Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2173 in Systemic Lupus Erythematosus
NCT07299422Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2026
- Primary completion
- Mar 2028
- Modality
- Biological product
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-2173 in systemic lupus erythematosus (SLE), sponsored by Hengrui Therapeutics. Started Apr 2026; status: recruiting.
02
Drugs
SHR-2173
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07299422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07299422.